UB-VV400

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameUB-VV400
Drug Alias NameUB-VV400
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionAnti-CD22
TargetsCD22
Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesUmoja BioPharma IncIaso Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIaso Biotherapeutics LtdUmoja BioPharma IncNanjing Iaso Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A